# A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma

Source: https://onco.cc/trials/nct05664243/  
OnCo record `nct05664243` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Autologous genetically modified gamma-delta T cells in glioma & glioblastoma, run by In8bio Inc., active and no longer recruiting.

## Summary

A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma is a phase 1/2 interventional study registered as NCT05664243 by In8bio Inc., with 4 participants enrolled, started 2023-09-08 and due to reach its primary completion in 2025-12. Interventions recorded: Autologous genetically modified gamma-delta T cells and Allogeneic genetically modified gamma-delta T cells.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05664243
- Phase: 1/2
- Setting: A Phase 1b / 2 Open-label Study to Investigate the Safety, Tolerance and Efficacy of Drug Resistant Immunotherapy (DRI) With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide (TMZ) in Subjects With Recurrent or Newly Diagnosed Glioblastoma
- Sponsor: In8bio Inc.
- Enrolled: 4

## Sources

- ClinicalTrials.gov NCT05664243: https://clinicaltrials.gov/study/NCT05664243

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05664243.json